As of 2026-07-17, the Fair Value of Lineage Cell Therapeutics Inc (LCTX) is -1.28 USD. This value is based on the Peter Lynch's Fair Value formula. With the current market price of 1.17 USD, the upside of Lineage Cell Therapeutics Inc is -209.27%.
With the market price of 1.17 USD and our fair value calculation, Lineage Cell Therapeutics Inc (LCTX) is not a good investment. Investing in LCTX stocks now will result in a potential loss of 209.27%.
Note: valuation result may not be accurate due to the company's negative EPS.
Peter Lynch's formula is:
The earnings growth rate we use in the formula is the average growth rate of net income/earnings over the last 5 years. If the average growth rate is smaller than 5%, we set it to 5%. If it is larger than 25%, we set it to 25%. If the TTM EPS is negative, Peter Lynch Fair Value's result can be unreliable.
| Historical Earnings | ||||||
| 2023-12-31 | 2024-12-31 | 2025-12-31 | - | - | 5Y Avg | |
| Net income | -18.61 | -63.53 | - | - | -41.07 | |
| YoY growth | 13.39% | -241.41% | - | - | -114.01% | |
| Market Cap (mil) | 291.68 |
| P/E | |
| Forward P/E |
| EPS | -0.26 |
| Avg earnings growth rate | -114.01% |
| TTM earnings | -63.74 |